Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blister test reveals sex differences in inflammation healing

NCT ID NCT05597098

Knowledge-focused Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-phase study at Queen Mary University of London aims to understand why men and women respond differently to inflammation, which may affect heart disease risk. Researchers will apply a small amount of cantharidin (a blister-inducing chemical) to the skin of 34 healthy volunteers aged 18-45. They will then compare blister size, fluid, and immune cells between sexes over 24-72 hours to see if women resolve inflammation faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cantharidin (a blister-inducing solution)
What this could lead to
If successful, this could help explain why men and women have different rates of heart disease, pointing toward sex-specific treatments for inflammation.
What could go wrong
This is a very early, small study (34 people) in healthy volunteers, not patients. It only measures blisters, not real disease outcomes, so results may not apply to actual illness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy male and female volunteers 2. Aged 18-45 3. Volunteers who are willing to sign the consent form Exclusion Criteria: 1. Healthy subjects unwilling to consent 2. Pregnant, or any possibility that a subject may be pregnant unless in the latter case a pregnancy test is performed with a negative result 3. Current breast feeding 4. History of any serious illnesses, including recent infections or trauma 5. Subjects taking systemic medication (other than the oral contraceptive pill) 6. Subjects with recent (2 weeks) or current antibiotic use 7. Subjects with any history of a blood-borne infectious disease such as Hepatitis B or C virus, or HIV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammation

Contacts and locations

Locations

  • The William Harvey Research Institute

    London, EC1M 6BQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.